Loading clinical trials...
Loading clinical trials...
As a follow-on study to NCT01416038, this study is designed to identify the optimal dosage of immunotherapeutic survivin vaccine DPX-Survivac and low dose oral cyclophosphamide. The combination treatm...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT06710548 · Ovarian Cancer, Advanced Ovarian Carcinoma, and more
NCT06915025 · Epithelial Ovarian Cancer, Ovarian Cancer, and more
NCT02637934 · Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT05080946 · Ovarian Cancer, Fallopian Tube Cancer, and more
NCT05281471 · Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, and more
Winthrop University Hospital
Mineola, New York
Lenox Hill Hospital
New York, New York
Princess Margaret Cancer Centre
Toronto, Ontario
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions